Several developments have been proposed to improve cancer chemotherapy. They include: increased drug dosage (Powis, 1985) ; altered schedules of administration, such as prolonged infusions or multiple injections (Desoize & Garrett, 1989; Lokich et al., 1989; Clark & Slevin, 1987) ; and pharmacokinetic monitoring. Clinical pharmacokinetics enables the individual distribution and metabolism of drugs to be studied and the correlation of pharmacokinetic measurements with the drug's efficacy and toxicity. Here we report an analysis of the pharmacokinetics of Etoposide (VP 16) in 32 courses of treatment in 14 patients with solid tumours.
Fourteen patients were the subjects of the pharmacokinetic studies, 10 had non-small cell lung cancer, one a nonHodgkin's lymphoma, one a breast cancer and in two patients the site of primary cancer was unknown. Seven patients responded to chemotherapy and seven did not respond. The pharmacokinetics were studied on 32 occasions. Creatinine clearance was measured during the first 24 h of infusion in the last 10 of these studies. Pharmacokinetics were studied on one to three occasions per patient (Table I) .
Etoposide was infused for 5 days (50 mg m2 day-' x 5), one course was given every 4 weeks. Two volumetric pumps were used for each continuous infusion. Etoposide was given with cisplatin (CDDP, 20 mg m-2 day-' x 5), except in one patient treated with cyclophosphamide (CPM, 500 mg at JO).
Toxicity (myelosuppression) and drug efficacy were evaluated after one and three courses respectively, according to WHO criteria (Miller et al., 1981 (Figure 1 ). The plateau was reached quickly, although etoposide terminal half-life is approximately 8 h (Clark & Slevin, 1987) . The etoposide concentration was not constant throughout the duration of the infusion; the mean coefficent of variation was 15% (6-33%).
There was considerable variation between patients. As a consequence, patient doses were not significantly correlated to plasma etoposide concentration (r = 0.325, n.s.) for all the kinetic studies, even when the dose was expressed per square metre.
Both etoposide plasma concentration and etoposide AUC were clearly correlated with serum creatinine concentration (r = 0.579, P<0.001 and r= 0.472, P<0.01 respectively) which is probably the result of 50% of the etoposide being cleared by the kidney (Clark & Slevin, 1987) .
Toxicity was significantly higher in responders as compared to non-responders, but it was unrelated to the pharmacokinetics, whereas efficacy was related to several variables. In responders etoposide concentration was higher as early as the first assay, but it was significantly related with efficacy only from day 3 (see Table I and Figure 1 ). Etoposide mean concentration, AUC and clearance were also significantly higher in responders, as well as the creatinine concentration and clearance (Table I) plasma concentration and AUC; a similar relationship was established for teniposide by Rodman et al. (1987) . Our data suggest that renal impairment enhances etoposide concentration, as also reported by D 'Incalci et al. (1986) , and thus increases the chance of a response. This hypothesis was confirmed by the correlations observed between creatinine concentration (and clearance) and etoposide concentration, and efficacy. In this study CDDP did not cause impaired renal function.
CDDP and CPM were probable contributors to chemotherapy efficacy but cannot be estimated. For this reason we conclude that when etoposide concentration and AUC were low the treatment was not efficient: six out of seven nonresponders compared to two out of seven responders had plasma concentrations<2.5 ymol 1'. These results led us to initiate a phase I/II study for an adaptative control of etoposide administration, with a dose adjustment at 28 h as proposed by Ratain et al. (1989) .
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